GPCR Therapeutics Announces Out-Licensing Agreement with Bridge Biotherapeutics in Idiopathic Pulmonary Fibrosis
December 14, 2023 03:29 ET
|
GPCR Therapeutics
SEOUL, Korea and REDWOOD CITY, Calif., Dec. 14, 2023 (GLOBE NEWSWIRE) -- GPCR Therapeutics, Inc., a clinical-stage international biopharmaceutical company, announces it enters into an out-licensing...
GPCR Therapeutics Announces Publication on Improving Hematopoietic Stem Cell Mobilization Using Propranolol with GPC-100
October 26, 2023 03:33 ET
|
GPCR Therapeutics
SEOUL, Korea and REDWOOD CITY, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- GPCR Therapeutics, Inc., a clinical stage international biopharmaceutical company with an innovative approach to developing...
GPCR Therapeutics Expands Pipeline into Fibrosis with a Combination Approach Targeting LPA1
October 10, 2023 03:00 ET
|
GPCR Therapeutics
SEOUL, Korea and REDWOOD CITY, Calif., Oct. 10, 2023 (GLOBE NEWSWIRE) -- GPCR Therapeutics, Inc., a clinical-stage, international biopharmaceutical company, announced today the expansion of its...
GPCR Therapeutics Announces Publication in Nature Scientific Reports on Novel Anticancer Therapy
March 15, 2023 04:00 ET
|
GPCR Therapeutics
SEOUL, Korea and REDWOOD CITY, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- GPCR Therapeutics, Inc., a clinical stage, international biopharmaceutical company focused on targeting G Protein Coupled...